Gosset Year Founded
2017
Ownership
Private
Employees
~100
Therapeutic Areas
Stage
Phase 1
Modalities
Skyhawk Therapeutics General Information
Lead candidate SKY-0515 demonstrated 72% reduction in HTT mRNA in Phase 1 Healthy Volunteer MAD study. SKY-1214 shows synergistic anti-cancer activity in preclinical studies for hematologic cancers.
Contact Information
Drug Pipeline
SKY-0515
Phase 1Key Partnerships
Bristol Myers Squibb, Biogen, Genentech, Ipsen, Merck, Sanofi, Takeda, Vertex
Skyhawk Therapeutics Funding
| Deal Type | Date | Amount | Status | Stage |
|---|
To view Skyhawk Therapeutics's complete valuation and funding history, request access »
Skyhawk Therapeutics Investors
Notable investors include long-term venture capital funds focused on biotech innovation; specific names not listed but referenced as leading long-term investors.
Investor Type: Venture Capital
Holding: Minority